Molecular Biology of the Cell 2011-04-15

Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/β-catenin signaling.

Keli Kolegraff, Porfirio Nava, My N Helms, Charles A Parkos, Asma Nusrat

Index: Mol. Biol. Cell 22 , 1121-1134, (2011)

Full Text: HTML

Abstract

Desmocollin-2 (Dsc2) and desmoglein-2 (Dsg2) are transmembrane cell adhesion proteins of desmosomes. Reduced expression of Dsc2 has been reported in colorectal carcinomas, suggesting that Dsc2 may play a role in the development and/or progression of colorectal cancer. However, no studies have examined the mechanistic contribution of Dsc2 deficiency to tumorigenesis. Here we report that loss of Dsc2 promotes cell proliferation and enables tumor growth in vivo through the activation of Akt/β-catenin signaling. Inhibition of Akt prevented the increase in β-catenin-dependent transcription and proliferation following Dsc2 knockdown and attenuated the in vivo growth of Dsc2-deficient cells. Taken together, our results provide evidence that loss of Dsc2 contributes to the growth of colorectal cancer cells and highlight a novel mechanism by which the desmosomal cadherins regulate β-catenin signaling.


Related Compounds

Related Articles:

Alpha-lipoic acid activates eNOS through activation of PI3-kinase/Akt signaling pathway.

2015-01-01

[Vascul. Pharmacol. 64 , 28-35, (2015)]

Neuritogenic Activity of Tetradecyl 2,3-Dihydroxybenzoate Is Mediated through the Insulin-Like Growth Factor 1 Receptor/Phosphatidylinositol 3 Kinase/Mitogen-Activated Protein Kinase Signaling Pathway.

2015-08-01

[Mol. Pharmacol. 88 , 326-34, (2015)]

Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.

2015-04-01

[Eur. J. Neurosci. 41(7) , 965-75, (2015)]

Urocortin 2 stimulates nitric oxide production in ventricular myocytes via Akt- and PKA-mediated phosphorylation of eNOS at serine 1177.

2014-09-01

[Am. J. Physiol. Heart Circ. Physiol. 307(5) , H689-700, (2014)]

Deciphering combinations of PI3K/AKT/mTOR pathway drugs augmenting anti-angiogenic efficacy in vivo.

2014-01-01

[PLoS ONE 9(8) , e105280, (2014)]

More Articles...